Prognostic Value of Each Codon-specific KRAS Mutation in Colorectal Cancer

Colorectal Cancer Clinical Trial

Official title: Does KRAS Codon 13 Mutation Have Prognostic Value in Colorectal Cancer?

Status Completed

Clinical Trial Summary

This retrospective study reviewed 3,144 patients who underwent surgery for colorectal cancer. This study was designed to comprehend the clinicopathological characteristics associated with individual codon-specific KRAS mutations in colorectal cancer.

Clinical Trial Description

This study was designed to comprehend the clinicopathological characteristics associated with individual codon-specific KRAS mutations in colorectal cancer including codon 12, 13, and 61. Furthermore, the main objective of this study was to determine whether KRAS codon 13 mutation could serve as a prognostic biomarker of colorectal cancer in a relatively large cohort of subjects. Overall survival (OS) and recurrence-free survival (RFS) were calculated from the date of surgery and compared using the Kaplan-Meier method and log-rank test. For analysis of risk factors for tumor recurrence, Cox proportional hazards regression model was used with the covariance input criterion set as < 0.1. Patients were subdivided based on primary tumor location (colon versus rectum), and MSI status (MSS/MSI-low versus MSI-high). ;

Related Conditions & MeSH terms

• Colorectal Cancer
• Colorectal Neoplasms

• NCT number: NCT05657210
• Study type: Observational
• Source: Seoul National University Bundang Hospital
• Status: Completed
• Start date: January 1, 2009
• Completion date: December 31, 2021